Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty
Launched by CORIN · Jan 2, 2024
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is looking at how well a new technology for balancing soft tissues works in patients undergoing robotic-assisted total knee replacement surgery. The main aim is to find out how accurate this technology is, whether it uses sensors or not, and to see how patients feel and recover after their surgery. Participants will fill out surveys about their health before and after the procedure to help researchers understand the effects of this technology.
To participate in the trial, patients need to be planning to have either their first knee replacement or a revision of a previous one and must be able to agree to the study rules. However, certain people may not be eligible, such as those with a high body weight (BMI over 45) or specific medical conditions that could affect the surgery or recovery. Throughout the study, participants can expect to share their experiences and outcomes, helping to advance knowledge about this innovative approach to knee surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient must be a candidate for a primary or revision total knee arthroplasty
- • 2. Patient is able and willing to sign the informed consent and follow study procedures
- • 3. Patient's joint must be anatomically and functionally suited to receive the selected implant and accommodate use of the robotic assistance
- Exclusion Criteria:
- • 1. Patient has a BMI \>45.
- • 2. Significant neurological or musculoskeletal disorders or disease that may interfere with total knee arthroplasty survival, adversely affect gait or weight bearing, (i.e. Paget's disease, Charcot's disease, muscular dystrophy, multiple sclerosis).
- • 3. The presence of highly communicable disease or diseases that may limit follow-up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis, HIV, etc.).
- • 4. Presence of known active metastatic or neoplastic disease.
- • 5. Cancer patients unless they have received curative treatment and have no evidence of recurrence for 5 years.
- • 6. Patient has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease).
- • 7. Patient has an active infection or joint sepsis.
- • 8. Patient has muscular, neurological or vascular deficiencies which compromise the affected extremity (i.e., Parkinson's Disease, Multiple Sclerosis, and Charcot joints).
- • 9. Patients with allergies or suspected sensitivity to any patient-contacting component of the implant to be used in the study Has known sensitivity to implants or the materials in the device including but not limited to: Ti, Al, V, Co, Cr, Mo, Ni and Si3N4.).
- • 10. Patients who are currently on medical leave from their employment due to Worker's Compensation.
- • 11. Patients who are at high risk for poor healing or confounding outcomes or at excessive risk for surgery (e.g., clinically significant/being actively treated for renal, hepatic, cardiac, hematologic, or neurologic disease or poorly controlled diabetes (HbA1c \> 8 mg/dL) or previous history of joint infection).
- • 12. Patients who are known drug or alcohol abusers or with psychological disorders as defined by DSM V that could affect follow-up care or treatment outcomes.
- • 13. Patients who are currently involved in another clinical study with an investigational device.
- • 14. Patients with current litigation pending related to medical treatment of any sort.
- • 15. Patients, who, in the opinion of the investigator, will not be able to complete the study per the protocol.
About Corin
Corin is a leading medical technology company specializing in the development of innovative solutions for the management of cardiovascular diseases. With a strong focus on improving patient outcomes, Corin leverages advanced data analytics and cutting-edge technology to enhance the precision and effectiveness of cardiac care. The company's commitment to research and development drives its clinical trials, aimed at validating and optimizing its products, ensuring they meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and institutions, Corin strives to advance the field of cardiology and provide healthcare providers with the tools they need to deliver exceptional patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Crosse, Wisconsin, United States
Rochester, Michigan, United States
Flagstaff, Arizona, United States
Middlebury, Connecticut, United States
Garden City, New York, United States
Oklahoma City, Oklahoma, United States
Rochester,, Michigan, United States
Patients applied
Trial Officials
Jan A Koenig, MD
Principal Investigator
NYU LANGONE-LONG ISLAND
Jeffrey H DeClaire, MD
Principal Investigator
DeClaire LaMacchia Orthopaedic Institute
Amber Randall, MD
Principal Investigator
Granite Orthopaedics
Corey Ponder, MD
Principal Investigator
Oklahoma Sports and Orthopedics Institute
John Keggi, MD
Principal Investigator
Orthopaedics New England
Jeffrey Lawrence, MD
Principal Investigator
Gundersen Lutheran Medical Foundation, Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported